Request Trial
illustration-rocket-astronaut
1 May 2012AsiaArchana Shanker

A step into the unknown: India's first compulsory licence

The licence was granted to Natco Pharma, a generic drug company, for sorafenib tosylate, a life-extending drug developed, patented and launched by Bayer Corporation. This drug is sold under the trade name of Nexavar and is used for the treatment of advanced-stage kidney and liver cancer.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
AstraZeneca partners with Chinese firm ahead of next obesity race
5 February 2026   The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.
Asia
Chinese biotech strikes billion dollar deal in nextgen cancer race
20 January 2026   Magic Circle and major US firm among dealmakers who worked on the licensing agreement for a bispecific antibody candidate, marking another significant outbound licensing deal from China’s biopharma sector.
Asia
Novo Nordisk secures China win ahead of key patent expiration
6 January 2026   Danish pharma giant notches an important victory in a huge market for semaglutide, but faces a patent cliff and mounting challenges across India, Canada and the US.


Editor's picks

Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026

Editor's picks

Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026
Americas
Bayer enters COVID-19 vaccine row with three suits against major drugmakers
8 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025

More features

Novartis takes aim at Tafinlar generic in latest suit
AstraZeneca partners with Chinese firm ahead of next obesity race
AI is transforming top 100 innovators, shows index
Novartis win blocks generics relitigating $7.8bn heart drug patent
Rooted in rights: Lessons from plant patent infringement and invalidity cases
Skinny labels, big stakes: SCOTUS lines up the case of the year
Chinese biotech strikes billion dollar deal in nextgen cancer race
Speciality pharma firm stumbles on bid to enforce Belbuca ruling